Barriers to the use of breast cancer risk reduction therapies

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 7, 2015, Pages 927-935

  Bambhroliya, Arvind ^a   Chavez MacGregor, Mariana ^b   Brewster, Abenaa M ^a,c  

^a Departmentc of A Clinical Cancer Prevention   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CONTINUING EDUCATION; HUMAN; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CLINICAL PRACTICE; FEMALE;

SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST NEOPLASMS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84938091107     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0107     Document Type: Review

References (57)

1. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
2. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-824.
3. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
4. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-97.
5. Vogel VG, Constantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
6. Vogel VG, Constantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.
7. Goss, P.E., et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-2391.
8. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383:1041-1048.
9. Moyer VA; for the U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698-708.
10. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29:2327-2333.
11. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:2942-2962.
12. Bevers TB, Ward JH, Arun BK, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1, 2015. Available at: NCCN.org. Accessed June 8, 2015.
13. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-880.
14. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532.
15. Nichols HB, DeRoo LA, Scharf DR, Sandler DP. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst 2015;107:354.
16. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-3095.
17. Goldenberg VK, Seewaldt VL, Scott V, et al. Atypia in random periareolar fineneedle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007;16:1032-1034.
18. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004;100:1800-1806.
19. Layeequr Rahman R, Crawford S. Chemoprevention Indication Score: a userfriendly tool for prevention of breast cancer - pilot analysis. Breast 2009;18:289-293.
20. Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park) 2011;25:1051-1058.
21. Owens WL, Gallagher TJ, Kincheloe MJ, Ruetten VL. Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract 2011;7:85-88.
22. Razzaboni E, Toss A, Cortesi L, et al. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J 2013;19:10-21.
23. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 2014;110:1681-1687.
24. Roetzheim RG, Lee JH, Fulp W, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast 2015;24:51-56.
25. Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer [published online ahead of print February 26, 2015]. Eur J Cancer Prev, in press.
26. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat 2012;136:627-633.
27. Runowicz CD, Costantino JP, Wickerham DL, et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol 2011;205:535.e1-5.
28. Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-2265.
29. Corbelli J, Borrero S, Bonnema R, et al. Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J Womens Health (Larchmt) 2014;23:746-752.
30. Brewster AM, Christo DK, Lai H, Helzlsouer K. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Cancer 2005;15:1147-1153.
31. Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev 2007;31:375-383.
32. Kaplan CP, Haas JS, Perez-Stable EJ, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41:7-15.
33. Ravdin PM. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res (Phila) 2010;3:686-688.
34. American Society of Clinical Oncology; Ganz PA, Kwan L, et al. The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol 2006;24:2948-2957.
35. Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004;22:4951-4957.
36. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-585.
37. Heisey R, Pimlott N, Clemons M, et al. Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician 2006;52:624-625.
38. Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005;103:1996-2005.
39. Cyrus-David MS, Strom SS. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psychooncology 2001;10:521-533.
40. Fagerlin A, Zikmund-Fisher BJ, Nair V, et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 2010;119:613-620.
41. Temple R. Cancer chemoprevention-the cardiovascular model. Cancer Prev Res (Phila) 2011;4:307-310.
42. Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Research 2013;15:R74.
43. Ralph AF, Ager B, Bell ML, et al. Women's preferences for selective estrogen reuptake modulators: an investigation using protective motivation theory. Patient Educ Couns 2014;96:106-112.
44. Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med 2006;21:779-785.
45. Fasching PA, von Minckwitz G, Fischer T, et al. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat 2007;101:95-104.
46. Tjia J, Micco E, Armstrong K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat 2008;108:435-453.
47. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-3095.
48. McKay A, Martin W, Latosinsky S. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat 2005;94:153-159.
49. Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat 2011;127:681-688.
50. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52-62.
51. Gleason MX, Mdzinarishvili T, Sherman S. Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses. PLoS One 2012;7:e49359.
52. Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res 2014;16:446.
53. Meyskens FL Jr, Curt GA, Brenner DE, et al. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) 2011;4:311-323.
54. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-964.
55. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007;99:1695-1705.
56. Tyrer J, Duffy SW, Cuzick K. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
57. Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 2005;3:242-7.